Journal
LEUKEMIA
Volume 35, Issue 7, Pages 1907-1924Publisher
SPRINGERNATURE
DOI: 10.1038/s41375-020-01080-6
Keywords
-
Categories
Funding
- Jazz Pharmaceuticals
- University of Maryland Greenebaum Comprehensive Cancer Center Support grant [P30CA134274]
- State of Maryland's Cigarette Restitution Funds
Ask authors/readers for more resources
The combination therapy of venetoclax and Pegylated Crisantaspase showed synergistic anti-leukemic activity in complex karyotype acute myeloid leukemia, both in vitro and in vivo. This novel approach holds promise as a potential new treatment strategy for this challenging subtype of leukemia.
Complex karyotype acute myeloid leukemia (CK-AML) has a dismal outcome with current treatments, underscoring the need for new therapies. Here, we report synergistic anti-leukemic activity of the BCL-2 inhibitor venetoclax (Ven) and the asparaginase formulation Pegylated Crisantaspase (PegC) in CK-AML in vitro and in vivo. Ven-PegC combination inhibited growth of multiple AML cell lines and patient-derived primary CK-AML cells in vitro. In vivo, Ven-PegC showed potent reduction of leukemia burden and improved survival, compared with each agent alone, in a primary patient-derived CK-AML xenograft. Superiority of Ven-PegC, compared to single drugs, and, importantly, the clinically utilized Ven-azacitidine combination, was also demonstrated in vivo in CK-AML. We hypothesized that PegC-mediated plasma glutamine depletion inhibits 4EBP1 phosphorylation, decreases the expression of proteins such as MCL-1, whose translation is cap dependent, synergizing with the BCL-2 inhibitor Ven. Ven-PegC treatment decreased cellular MCL-1 protein levels in vitro by enhancing eIF4E-4EBP1 interaction on the cap-binding complex via glutamine depletion. In vivo, Ven-PegC treatment completely depleted plasma glutamine and asparagine and inhibited mRNA translation and cellular protein synthesis. Since this novel mechanistically-rationalized regimen combines two drugs already in use in acute leukemia treatment, we plan a clinical trial of the Ven-PegC combination in relapsed/refractory CK-AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available